摘要
在过去的近10年中，尽管多发性骨髓瘤（MM）的治疗取得了较大进步，患者的缓解率明显提高，但总的生存期（OS）没有明显改善。随着对MM发病机制研究的深入，以沙利度胺和硼替佐米为代表的靶向治疗药物的应用，使MM的完全缓解率明显提高，CS得到延长，MM成为一种趋于治愈性的疾病。
In the past decades, the response rate of multiple myeloma （MM） to chemotherapy has been rapidly improved, but the complete remission （CR） was still low, and the overall survival （OS） was still short. As the usage of thalidomide and bortezomib, CR is improved and OS is extended. It is regarded that MM is a cancer which could be possibly cured. In this article, the target therapy of MM was reviewed.
出处
《白血病．淋巴瘤》
CAS
2009年第9期523-528,共6页
Journal of Leukemia & Lymphoma
